[1]	中华医学会外科学分会胃肠外科学组, 中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会, 中国临床肿瘤学会胃肠间质瘤专家委员会, 等. 胃肠间质瘤全程化管理中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(10): 1109-1119. DOI: 10.19538/j.cjps.issn1005-2208.2020.10.01. 本文引用 [1]

[2]	von Mehren M, Joensuu H. Gastrointestinal stromal tumors[J]. J Clin Oncol, 2018, 36(2): 136-143. DOI: 10.1200/JCO.2017.74.9705. 本文引用 [1]

[3]

National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Gastrointestinal stromal tumors (GISTs),version 1.2025[EB/OL]. [2025-02-07](2026-05-18) https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf. https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf 本文引用 [4]

[4]	Bartel T, Pabst KM, Barg C, et al. [68Ga]Ga-FAPI-46 PET/CT of patients with gastrointestinal stromal tumors in comparison to 2-[18F]FDG PET/CT and contrast-enhanced CT: Results from a prospective observational study[J]. J Nucl Med, 2026, 67(2):210-216. DOI: 10.2967/jnumed.125.270850. 本文引用 [1]

[5]	Wang R, Kang W, Liu Z, et al. Head-to-head comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in patients with gastrointestinal stromal tumors: A prospective study[J]. J Nucl Med, 2025, 66(2): 201-206. DOI: 10.2967/jnumed.124.267810. 本文引用 [1]

[6]	中国研究型医院学会消化道肿瘤专业委员会, 中国医师协会外科医师分会多学科综合治疗专业委员会. 胃肠间质瘤多学科综合治疗协作组诊疗模式专家共识[J]. 中国实用外科杂志, 2017, 37(1):39-41. DOI: 10.19538/j.cjps.issn1005-2208.2017.01.13. 本文引用 [1]

[7]	Etherington MS, DeMatteo RP. Tailored management of primary gastrointestinal stromal tumors[J]. Cancer, 2019, 125(13):2164-2171. DOI: 10.1002/cncr.32067. 本文引用 [1]

[8]	曹晖, 汪明. 靶向药物治疗时代的柳叶刀—手术在晚期胃肠间质瘤治疗中的地位[J]. 中华胃肠外科杂志, 2016, 19(11): 1211-1216. DOI: 10.3760/cma.j.issn.1671-0274.2016.11.003. 本文引用 [1]

[9]	Du CY, Zhou Y, Song C, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China[J]. Eur J Cancer, 2014, 50(10): 1772-1778. DOI: 10.1016/j.ejca.2014.03.280. 本文引用 [1]

[10]	中国心胸血管麻醉学会非心脏麻醉分会, 中国医师协会心血管内科医师分会, 中国心血管健康联盟. 抗血栓药物围手术期管理多学科专家共识[J]. 中华医学杂志, 2020, 100(39): 3058-3074. DOI: 10.3760/cma.j.cn112137-20200528-01704. 本文引用 [1]

[11]	Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease,version 2.2024,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(7): 483-506. DOI: 10.6004/jnccn.2024.0046. 本文引用 [1]

[12]	Gustafsson UO, Rockall TA, Wexner S, et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations 2025[J]. Surgery, 2025, 184: 109397. DOI: 10.1016/j.surg.2025.109397. 本文引用 [1]

[13]	中国研究型医院学会机器人与腹腔镜外科专业委员会, 《中华消化外科杂志》编辑委员会. 精准外科胃癌手术加速康复外科专家共识(2025版)[J]. 中华消化外科杂志, 2025, 24(10): 1221-1232. DOI: 10.3760/cma.j.cn115610-20250912-00580. 本文引用 [1]

[14]	Navarro LH, Bloomstone JA, Auler JO, et al. Perioperative fluid therapy: A statement from the international Fluid Optimization Group[J]. Perioper Med, 2015, 4: 3. DOI: 10.1186/s13741-015-0014-z. 本文引用 [1]

[15]	李冰, 齐志鹏, 周平红, 等. 内镜全层切除术治疗胃底部小及微小胃肠间质瘤价值探讨[J]. 中国实用外科杂志, 2017, 37(11): 1281-1285. DOI: 10.19538/j.cjps.issn1005-2208.2017.11.23. 本文引用 [1]

[16]	姚宏伟, 张忠涛. 直肠胃肠间质瘤不同手术入路的探索:从TME到TEM再到TaTME[J]. 中国实用外科杂志, 2018, 38(5): 578-581. DOI: 10.19538/j.cjps.issn1005-2208.2018.05.21. 本文引用 [1]

[17]	Elizabeth CW, Michael CG, Christopher LW, et al. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: A review[J]. JAMA Surg, 2017, 152 (7):691-697. DOI:10.1001/jamasurg.2017.0898. 本文引用 [2]

[18]	Sugisawa N, Tokunaga M, Makuuchi R, et al. A phase Ⅱ study of an enhanced recovery after surgery protocol in gastric cancer surgery[J]. Gastric Cancer, 2016, 19(3): 961-967. DOI: 10.1007/s10120-015-0528-6. 本文引用 [1]

[19]	Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria[J]. Surg Today, 2016, 46(6): 668-685. DOI: 10.1007/s00595-015-1236-x. 本文引用 [1]

[20]	中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版)[J]. 肿瘤综合治疗电子杂志, 2018, 4(1):31-43. 本文引用 [1]

[21]	Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor[J]. Hum Pathol, 2008, 39(10):1411-1419. DOI:10.1016/j.humpath.2008.06.025. 本文引用 [1]

[22]	Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classification of tumours of soft tissue and bone[M]. 4th ed. Lyon: LARC Press, 2013: 164-167. 本文引用 [1]

[23]	Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites[J]. Semin Diagn Pathol, 2006, 23(2): 70-83. DOI:10.1053/j.semdp.2006.09.001. 本文引用 [1]

[24]	侯英勇, 朱雄增. 胃肠间质瘤恶性程度的判断及其对预后的影响[J]. 中国实用外科杂志, 2010, 30(4): 265-269. 本文引用 [1]

[25]	Blay JY, Kang YK, Nishida T, von Mehren M. Gastrointestinal stromal tumours[J]. Nat Rev Dis Primers, 2021, 7(1): 22. DOI: 10.1038/s41572-021-00254-5. 本文引用 [1]

[26]	中国临床肿瘤学会胃肠间质瘤专家委员会, 中国抗癌协会胃肠间质瘤专业委员会, 中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 胃肠间质瘤基因检测与临床应用的中国专家共识(2021版)[J]. 临床肿瘤学杂志, 2021, 26(10): 920-927. DOI: 10.3969/j.issn.1009-0460.2021.10.010. 本文引用 [1]

[27]	Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol, 2022, 33(1): 20-33. DOI: 10.1016/j.annonc.2021.09.005. 本文引用 [1]

[28]	范江彬, 支小飞, 陈思俊, 等. 循环肿瘤细胞监测在胃肠间质瘤靶向治疗中的意义[J]. 中华胃肠外科杂志, 2021, 24(9):789-795. DOI: 10.3760/cma.j.cn.441530-20201209-00655. 本文引用 [1]

[29]	Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial[J]. JAMA, 2012, 307(12): 1265-1272. DOI: 10.1001/jama.2012.347. 本文引用 [1]

[30]	Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised,primary gastrointestinal stromal tumour: A randomised,double-blind,placebo-controlled trial[J]. Lancet, 2009, 373(9669): 1097-1104. DOI: 10.1016/S0140-6736(09)60598-6. 本文引用 [1]

[31]	Blay JY, Schiffler C, Bouché O, et al. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse[J]. Ann Oncol, 2024, 35(12): 1157-1168. DOI:10.1016/j.annonc.2024.08.2343. 本文引用 [1]

[32]

Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase Ⅱ trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT[J]. J Clin Oncol, 2008, 26(4):620-625. DOI:10.1200/JCO.2007.13.4403. 本文引用 [1]

[33]	Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A Meta-analysis of 1,640 patients[J]. J Clin Oncol, 2010, 28(7): 1247-1253. DOI: 10.1200/JCO.2009.26.1948. 本文引用 [1]

[34]

Qiu HB, Liang Z, Yang J, et al. Olverembatinib,a multikinase inhibitor that modulates lipid metabolism,in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: A phase Ⅰb study and translational research[J]. Signal Transduct Target Ther, 2025, 10(1): 361. DOI: 10.1038/s41392-025-02180-6. 本文引用 [1]

[35]	Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial[J]. Lancet, 2006, 368(9544): 1329-1338. DOI: 10.1016/S0140-6736(06)69446-4. 本文引用 [1]

[36]	Bauer S, Jones RL, Blay JY, et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): A randomized,open-label,phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(34): 3918-3928. DOI: 10.1200/JCO.22.00294. 本文引用 [1]

[37]	Yeh C, Chen M, Chen Y, et al. A phase Ⅱ trial of regorafenib in patients with metastatic and/or an unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17[J]. Oncotarget, 2017, 8(27): 44121-44130. DOI: 10.18632/oncotarget.17310. 本文引用 [1]

[38]

Demetri GD, Reichardt P, Kang Y, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international,multicentre,randomised,placebo-controlled,phase 3 trial[J]. Lancet, 2013, 381(9863): 295-302. DOI:10.1016/S0140-6736(12)61857-1. 本文引用 [1]

[39]	Choi H. Response evaluation of gastrointestinal stromal tumors[J]. Oncologist, 2008, 13(suppl 2): 4-7. DOI:10.1007/978-3-319-42632-7_6. 本文引用 [1]

[40]	中国医师协会外科医师分会胃肠道间质瘤诊疗专业委员会. 酪氨酸激酶抑制剂治疗胃肠间质瘤不良反应及处理中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21(8): 997-1013. DOI: 10.3760/cma.j.cn115610-20220523-00292. 本文引用 [1]

[41]	Novartis Pharmaceuticals Corporation. GLEEVEC-imatinib mesylate tablet,film coated[EB/OL]. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/383078. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/383078 本文引用 [1]

[42]	Pfizer Laboratories Div Pfizer Inc. SUTENT-sunitinib malate capsule[EB/OL]. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/397030. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/397030 本文引用 [1]

[43]	Bayer HealthCare Pharmaceuticals Inc. STIVARGA-regorafenib tablet,film coated[EB/OL]. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/395322. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/395322 本文引用 [1]

[44]	Blueprint Medicines Corporation. AYVAKIT-avapritinib tablet,film coated[EB/OL]. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/389603. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/389603 本文引用 [1]

[45]	Deciphera Pharmaceuticals LLC. QINLOCK-ripretinib tablet,film coated[EB/OL]. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/395319. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/395319 本文引用 [1]

[46]	Groenland SL, van Eerden RAG, Westerdijk K, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: A prospective multicenter study[J]. Ann Oncol, 2022, 33(10): 1071-1082. DOI: 10.1016/j.annonc.2022.06.010. 本文引用 [2]

[47]	陈志亮, 田红坤, 丁嘉宁, 等. 血药浓度监测指导下伊马替尼减量治疗胃肠间质瘤完整切除术后辅助治疗患者的疗效分析[J]. 中华胃肠外科杂志, 2024, 27(11): 1148-1154. DOI:10.3760/cma.j.cn441530-20240807-00273. 本文引用 [1]

[48]	Liu X, Pi M, Chen M, et al. The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation[J]. Oncologist, 2025, 30(7): 1-6. DOI: 10.1093/oncolo/oyaf176 本文引用 [1]

[49]	Xu T, Xie J, Jiang C, et al. Unveiling the impact of adherence: imatinib plasma levels and survival in postoperative gastrointestinal stromal tumor (GIST) patients[J]. Br J Cancer, 2025, 133(9): 1307-1316. DOI: 10.1038/s41416-025-03173-4. 本文引用 [1]

[50]	Wang Y, Zhang P, Han Y, et al. Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice: A cross-sectional study[J]. Chemotherapy, 2019, 64(4): 197-204.DOI: 10.1159/000505177. 本文引用 [1]

[51]	Clarke WA, Chatelut E, Fotoohi AK, et al. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy[J]. Eur J Cancer, 2021, 157: 428-440. DOI: 10.1016/j.ejca.2021.08.033. 本文引用 [1]

[52]	中国药学会医院药学专业委员会, 中国药理学会治疗药物监测研究专业委员会, 《胃肠间质瘤靶向药物的治疗药物监测中国专家共识》编写组. 胃肠间质瘤靶向药物的治疗药物监测中国专家共识[J]. 中国医院药学杂志, 2021, 41(20): 2041-2049. DOI: 10.13286/j.1001-5213.2021.20.01. 本文引用 [1]

[53]	Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic Meta-analysis[J]. Cancer Chemother Pharmacol, 2010, 66(2):357-371. DOI: 10.1007/s00280-009-1170-y. 本文引用 [1]

[54]	Taguchi D, Inoue M, Fukuda K, et al. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities[J]. Int J Clin Oncol, 2020, 25(4): 531-540. DOI: 10.1007/s10147-019-01593-w. 本文引用 [1]

[55]	Zhang Q, Li F, Wang F, et al. Monitoring the plasma concentration of ripretinib and its metabolites in Chinese patients with gastrointestinal stromal tumors in a real-life setting[J]. Cancer, 2025, 131(suppl 3):e70149. DOI: 10.1002/cncr.35669. 本文引用 [1]

[56]	Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors[J]. J Clin Oncol, 2009, 27(19): 3141-3147. DOI: 10.1200/JCO.2008.20.4818. 本文引用 [1]

[57]	Bouchet S, Poulette S, Titier K, et al. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting[J]. Eur J Cancer, 2016, 57: 31-38. DOI: 10.1016/j.ejca.2015.12.029. 本文引用 [1]

[58]	丁嘉宁, 陈志亮, 田红坤, 等. 专病与非专病诊疗医师诊治中高危胃肠间质瘤预后对比研究[J]. 中国实用外科杂志, 2025, 45(5): 576-581. DOI: 10.19538/j.cjps.issn1005-2208.2025.05.18. 本文引用 [1]

[59]	中国医师协会外科医师分会胃肠间质瘤诊疗专家工作组. 胃肠间质瘤规范化外科治疗中国专家共识(2025版)[J]. 中国实用外科杂志, 2025, 45(1): 11-24. DOI: 10.19538/j.cjps.issn1005-2208.2025.01.03. 本文引用 [1]

[60]	Serrano C, Martín-Broto J, Asencio-Pascual JM, et al. 2023 GEIS Guidelines for gastrointestinal stromal tumors[J]. Ther Adv Med Oncol, 2023, 15: 17588359231192388. DOI:10.1177/17588359231192388. 本文引用 [1]

[61]	Judson I, Jones RL, Wong NACS, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines[J]. Br J Cancer, 2025, 132(1): 1-10. DOI:10.1038/s41416-024-02672-0. 本文引用 [1]